Literature DB >> 14968937

Mechanism of antiviral activities of 3'-substituted L-nucleosides against 3TC-resistant HBV polymerase: a molecular modelling approach.

Youhoon Chong1, Lieven Stuyver, Michael J Otto, Raymond F Schinazi, Chung K Chu.   

Abstract

Comparison of the active sites of the human HIV-1 reverse transcriptase (RT) and the homology-modelled hepatitis B virus (HBV) polymerase shows that the active sites of both enzymes are open to L-nucleosides, but the position where the 3'-substituent of the L-ribose projects in HBV polymerase is wider and deeper than HIV-1 RT, which enables the HBV polymerase to accommodate various 3'-substituted L-nucleosides. However, the space is not sufficient to accommodate a bulky 3'-substituent such as the 3'-azido group of L-3'-azido-3'-deoxythymidine. Analysis of the minimized structure of rtM204V HBV polymerase/3TCTP complex shows that, instead of the steric stress produced by rtV204, a loss of the van der Waals contact around the oxathiolane sugar moiety of 3TCTP caused by the mutation results in the disruption of the active site. Therefore, nucleosides, which are stabilized by additional specific interaction with the enzyme residues, can have more opportunities to circumvent the destabilization by the loss of hydrophobic interaction conferred by mutation. Specifically, the substitution at the 3'-position would be beneficial as the HBV polymerase has wide open space composed of the highly conserved motif (YMDD) where the 3'-substituents of the L-nucleosides project. As an example, our study shows that the 3'-fluorine atom contributes to the antiviral activity of L-3'-Fd4CTP against rtM204V HBV polymerase by readily compensating for the loss of the van der Waals interaction around the 2',3'-double bond through a formation of a hydrogen bond to the amide backbone of rtD205.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14968937     DOI: 10.1177/095632020301400603

Source DB:  PubMed          Journal:  Antivir Chem Chemother        ISSN: 0956-3202


  6 in total

1.  Pharmacokinetics of the antiviral agent beta-L-3'-fluoro-2',3'-didehydro-2',3'-dideoxycytidine in rhesus monkeys.

Authors:  Ghazia Asif; Selwyn J Hurwitz; Giuseppe Gumina; Chung K Chu; Harold M McClure; Raymond F Schinazi
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

Review 2.  Antiviral therapies: focus on hepatitis B reverse transcriptase.

Authors:  Eleftherios Michailidis; Karen A Kirby; Atsuko Hachiya; Wangdon Yoo; Sun Pyo Hong; Soo-Ok Kim; William R Folk; Stefan G Sarafianos
Journal:  Int J Biochem Cell Biol       Date:  2012-04-16       Impact factor: 5.085

3.  Inhibition of hepatitis B virus polymerase by entecavir.

Authors:  David R Langley; Ann W Walsh; Carl J Baldick; Betsy J Eggers; Ronald E Rose; Steven M Levine; A Jayne Kapur; Richard J Colonno; Daniel J Tenney
Journal:  J Virol       Date:  2007-01-31       Impact factor: 5.103

4.  Computational model of hepatitis B virus DNA polymerase: molecular dynamics and docking to understand resistant mutations.

Authors:  Pankaj R Daga; Jinsong Duan; Robert J Doerksen
Journal:  Protein Sci       Date:  2010-04       Impact factor: 6.725

5.  Inhibitory effect of Phyllanthus urinaria L. extract on the replication of lamivudine-resistant hepatitis B virus in vitro.

Authors:  Jaesung Jung; Nam Keun Kim; Sun Park; Ho-Joon Shin; Seong Gyu Hwang; Kyongmin Kim
Journal:  BMC Complement Altern Med       Date:  2015-07-29       Impact factor: 3.659

6.  Structural features in common of HBV and HIV-1 resistance against chirally-distinct nucleoside analogues entecavir and lamivudine.

Authors:  Yoshiaki Yasutake; Shin-Ichiro Hattori; Noriko Tamura; Kouki Matsuda; Satoru Kohgo; Kenji Maeda; Hiroaki Mitsuya
Journal:  Sci Rep       Date:  2020-02-20       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.